THE FOUNDATION FOR SECURE MARKETS®

#60250

Date: November 18, 2026

Subject: Adjusted PharmaCyte Biotech, Inc. – Cash In Lieu Settlement
Adjusted Option Symbol: PMCB1

Adjusted PharmaCyte Biotech, Inc. options were adjusted on November 13, 2026 (See OCC Information Memo #60203). The new deliverable became 1) 5 PharmaCyte Biotech, Inc. (PMCB) Common Shares 2) Cash in lieu of approximately 0.2632 fractional PMCB Shares. Only settlement of the cash portion of PMCB1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of $7.638 per whole PMCB share will be used to determine the cash in lieu amount at a rate of 0.2632. Accordingly, the cash in lieu amount is:

0.2632 x $7.638 = $2.01 per PMCB1 Contract

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of November 13, 2026 through November 18, 2026, to deliver the appropriate cash amount.

The cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

Terms of the PMCB1 options are as follows:

New Deliverable Per Contract: 1) 5 PharmaCyte Biotech, Inc. (PMCB) Common Shares
2) $2.01 Cash

Strike Prices: Unchanged

CUSIP: PMCB: 71715X302

Multiplier: 100 (i.e., a premium of 1.50 yields $150)

Settlement

The PMCB component of PMCB1 exercise/assignment activity from November 13, 2026 through November 17, 2026, has settled through National Security Clearing Corporation (NSCC). The $2.01 cash amount will be settled by OCC.

Pricing

The underlying price for PMCB1 will be determined as follows:

PMCB1 = 0.05 (PMCB) + 0.0201

For example, if PMCB closes at 5.42, the PMCB1 price would be calculated as follows:

PMCB1 = 0.05 (5.42) + 0.0201 = 0.29

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC's Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.